Dupilumab effective in treating severity, decreasing serum biomarkers in pediatric AD patients

Dupilumab was effective in improving disease severity and decreasing severity-associated serum biomarkers in pediatric atopic dermatitis (AD) patients after 28 weeks of treatment, according to real-world evidence from clinical practice.